Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus—A Narrative Review.
| Autor: | Brata, Roxana, Pascalau, Andrei Vasile, Fratila, Ovidiu, Paul, Ioana, Muresan, Mihaela Mirela, Camarasan, Andreea, Ilias, Tiberia |
|---|---|
| Předmět: |
WEIGHT loss
RENIN-angiotensin system RESEARCH funding HYPERTENSION HOSPITAL care DAPAGLIFLOZIN DIURESIS HEMODYNAMICS HEART failure CARDIOVASCULAR diseases risk factors CHRONIC kidney failure SYSTEMATIC reviews CARDIAC output MEDLINE SODIUM-glucose cotransporter 2 inhibitors DRUG efficacy MYOCARDIUM BLOOD pressure ONLINE information services AMBULATORY blood pressure monitoring DIABETES HEART ventricles GLYCOSURIA PHARMACODYNAMICS |
| Zdroj: | Healthcare (2227-9032); Dec2024, Vol. 12 Issue 23, p2464, 11p |
| Abstrakt: | Background: The current review aims to present the beneficial effects of SGLT2 inhibitors (dapagliflozin and empagliflozin) on several hemodynamic parameters such as blood pressure, filtration pressure at the level of the glomerular capillaries, and the improvement of the preload and afterload of heart muscle. In order to stop chronic kidney disease (CKD) from progressing, SGLT2 inhibitors have become an important disease-modifying treatment. Materials and methods: Recent clinical studies have shown the success of these drugs in treating heart failure, reducing the risk of cardiovascular events, hospitalization, and mortality. Results: The hemodynamic effects of SGLT2 inhibitors include a diuretic effect, due to reduced sodium reabsorption. Also, at this level, numerous studies have confirmed the beneficial effect of dapagliflozin in patients with chronic kidney disease, associated with a 44% reduced risk of progression in this pathology. SGLT2 inhibitors are associated with a reduction in blood pressure and weight loss, because of their diuretic effect, especially empagliflozin, which can explain the beneficial effects in patients with heart failure. In addition, mainly empagliflozin reduces stiffness and arterial resistance. Conclusions: Although the exact mechanism of action is unknown, SGLT2 inhibitors reduce the interstitial volume by blocking the tubular reabsorption of glucose. This leads to reduced blood pressure and enhanced endothelial function. Consequently, there have been improvements in hospitalization and fatality rates. Because of their beneficial effects, these medications have been guidelines for managing heart failure and chronic kidney disease. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|